CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,978 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00663546
NCT00663546N/ACompleted

Studies of P. Vivax and P. Falciparum Malaria in Cambodia

National Institute of Allergy and Infectious Diseases (NIAID)·observational·Posted Apr 22, 2008·Updated Aug 20, 2018

In Brief

An observational study for Malaria. Completed, enrolled 1,978 participants across 3 sites.

Detailed Summary

This study, conducted by the National Center for Parasitology, Entomology and Malaria Control of Cambodia s Ministry of Health and the National Institute of Allergy and Infectious Diseases, will explore whether the following factors confer protection against malaria and associated anemia: certain blood groups, the hemoglobin E variant, G6PD-deficiency and alpha-thalassemia. Malaria is caused by parasites (P. falciparum and P. vivax) that are transmitted to humans through mosquito bites. This protocol includes two studies, a cohort study and a P. vivax collection study. Individuals are eligible for enrollment in the studies as follows: Cohort study: Residents of all ages of Kandal, Ekapheap and Sangkumthmey villages (Thmar Da commune) who plan to remain in Thmar Da commune for the next 5 years. P. vivax collection study: 2 years of age and older Participating in NIAID protocol 05-I- N210 ( Severe Malaria and Anti-malarial Drug Resistance in Cambodia ) and diagnosed with P. vivax malaria Participants undergo the following procedures: Cohort study: Baseline evaluation, including the following: * Collection of demographic information * Malaria history, temperature measurement and review of current symptoms, if any * Blood draw of 300 microliters * Additional blood draw of 10 milliliters in selected adults 18 years of age and older Treatment with artesunate-piperaquine at a commune health post for subjects who develop malaria Contact once a year for 5 years to determine continued residency in Thmar Da commune P. vivax collection study: * Medical history and physical examination * Hemoglobin level measurement * Blood draw * Treatment with chloroquine * Blood draw 3 to 5 weeks after treatment in some patients 18 years of age or older

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMalaria
CountriesCambodia
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 22, 2008
Enrollment StartMar 24, 2008
Study CompletionDec 5, 2013
TodayJul 2, 2026
Posted 18.2 years ago